VISTA immune checkpoint blunts radiotherapy-induced antitumor immune response

Summary: Radiotherapy (RT) is a key treatment for solid neoplasms like head and neck cancer (HNC), but it can also activate and recruit immunosuppressive myeloid cells, causing treatment failure. In this study, we examine the role of V-domain immunoglobulin suppressor of T cell activation (VISTA) on...

Full description

Saved in:
Bibliographic Details
Main Authors: Dhanya K. Nambiar, Sainiteesh Maddineni, Jimpi Langthasa, Hongbin Cao, Vignesh Viswanathan, Junyan Liu, Md Tauhidul Islam, Nishant Mehta, Jessica Frank, Alexander Real, Tia Cheunkarndee, Eyiwunmi Eghonghon Laseinde, Bhushan Dharmadhikari, Dipti Thakkar, Jerome D. Boyd-Kirkup, Andrey Finegersh, Vasu Divi, John B. Sunwoo, John Aleman, Xiao-Jing Wang, Christina Kong, Lei Xing, Jennifer R. Cochran, Quynh-Thu Le
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Cell Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124725006643
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849433483602034688
author Dhanya K. Nambiar
Sainiteesh Maddineni
Jimpi Langthasa
Hongbin Cao
Vignesh Viswanathan
Junyan Liu
Md Tauhidul Islam
Nishant Mehta
Jessica Frank
Alexander Real
Tia Cheunkarndee
Eyiwunmi Eghonghon Laseinde
Bhushan Dharmadhikari
Dipti Thakkar
Jerome D. Boyd-Kirkup
Andrey Finegersh
Vasu Divi
John B. Sunwoo
John Aleman
Xiao-Jing Wang
Christina Kong
Lei Xing
Jennifer R. Cochran
Quynh-Thu Le
author_facet Dhanya K. Nambiar
Sainiteesh Maddineni
Jimpi Langthasa
Hongbin Cao
Vignesh Viswanathan
Junyan Liu
Md Tauhidul Islam
Nishant Mehta
Jessica Frank
Alexander Real
Tia Cheunkarndee
Eyiwunmi Eghonghon Laseinde
Bhushan Dharmadhikari
Dipti Thakkar
Jerome D. Boyd-Kirkup
Andrey Finegersh
Vasu Divi
John B. Sunwoo
John Aleman
Xiao-Jing Wang
Christina Kong
Lei Xing
Jennifer R. Cochran
Quynh-Thu Le
author_sort Dhanya K. Nambiar
collection DOAJ
description Summary: Radiotherapy (RT) is a key treatment for solid neoplasms like head and neck cancer (HNC), but it can also activate and recruit immunosuppressive myeloid cells, causing treatment failure. In this study, we examine the role of V-domain immunoglobulin suppressor of T cell activation (VISTA) on myeloid cells during RT. We discovered high VISTA expression on myeloid cells in the tumor microenvironment (TME) of both murine and human HNC, with RT increasing VISTA+ myeloid cells in the TME and circulation. Compared to VISTA+/+ mice, VISTA−/− mice showed improved tumor control with RT, with their macrophages and neutrophils exhibiting antitumorigenic properties on sc-RNA-seq analysis, especially with RT. Combining anti-VISTA antibodies (active or silent Fc) with RT (fractionated or ablative) significantly decreased tumor volume compared to either treatment alone in multiple preclinical models (HNC, breast cancer, and colorectal cancer), enhancing systemic antitumor immune response with augmented intra-tumoral T cell function through myeloid repolarization. Targeting VISTA could improve the efficacy of RT.
format Article
id doaj-art-3a19f3dce0404df6abd06110734032bc
institution Kabale University
issn 2211-1247
language English
publishDate 2025-07-01
publisher Elsevier
record_format Article
series Cell Reports
spelling doaj-art-3a19f3dce0404df6abd06110734032bc2025-08-20T03:27:01ZengElsevierCell Reports2211-12472025-07-0144711589310.1016/j.celrep.2025.115893VISTA immune checkpoint blunts radiotherapy-induced antitumor immune responseDhanya K. Nambiar0Sainiteesh Maddineni1Jimpi Langthasa2Hongbin Cao3Vignesh Viswanathan4Junyan Liu5Md Tauhidul Islam6Nishant Mehta7Jessica Frank8Alexander Real9Tia Cheunkarndee10Eyiwunmi Eghonghon Laseinde11Bhushan Dharmadhikari12Dipti Thakkar13Jerome D. Boyd-Kirkup14Andrey Finegersh15Vasu Divi16John B. Sunwoo17John Aleman18Xiao-Jing Wang19Christina Kong20Lei Xing21Jennifer R. Cochran22Quynh-Thu Le23Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA; Corresponding authorDepartment of Otolaryngology, Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USADepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USADepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USADepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USADepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USADepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USADepartment of Bioengineering, Stanford University Schools of Engineering and Medicine, Stanford, CA, USADepartment of Bioengineering, Stanford University Schools of Engineering and Medicine, Stanford, CA, USADepartment of Bioengineering, Stanford University Schools of Engineering and Medicine, Stanford, CA, USADepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USADepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USAHummingbird Bioscience, Singapore, SingaporeHummingbird Bioscience, Singapore, SingaporeHummingbird Bioscience, Singapore, SingaporeDepartment of Otolaryngology, Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USADepartment of Otolaryngology, Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USADepartment of Otolaryngology, Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USADepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USADepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA; Department of Pathology and Laboratory Medicine, University of California, Davis, School of Medicine, Davis, CA, USA; VA Northern California Health Care System, Sacramento, CA, USADepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USADepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USADepartment of Bioengineering, Stanford University Schools of Engineering and Medicine, Stanford, CA, USADepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA; Corresponding authorSummary: Radiotherapy (RT) is a key treatment for solid neoplasms like head and neck cancer (HNC), but it can also activate and recruit immunosuppressive myeloid cells, causing treatment failure. In this study, we examine the role of V-domain immunoglobulin suppressor of T cell activation (VISTA) on myeloid cells during RT. We discovered high VISTA expression on myeloid cells in the tumor microenvironment (TME) of both murine and human HNC, with RT increasing VISTA+ myeloid cells in the TME and circulation. Compared to VISTA+/+ mice, VISTA−/− mice showed improved tumor control with RT, with their macrophages and neutrophils exhibiting antitumorigenic properties on sc-RNA-seq analysis, especially with RT. Combining anti-VISTA antibodies (active or silent Fc) with RT (fractionated or ablative) significantly decreased tumor volume compared to either treatment alone in multiple preclinical models (HNC, breast cancer, and colorectal cancer), enhancing systemic antitumor immune response with augmented intra-tumoral T cell function through myeloid repolarization. Targeting VISTA could improve the efficacy of RT.http://www.sciencedirect.com/science/article/pii/S2211124725006643CP: CancerCP: Immunology
spellingShingle Dhanya K. Nambiar
Sainiteesh Maddineni
Jimpi Langthasa
Hongbin Cao
Vignesh Viswanathan
Junyan Liu
Md Tauhidul Islam
Nishant Mehta
Jessica Frank
Alexander Real
Tia Cheunkarndee
Eyiwunmi Eghonghon Laseinde
Bhushan Dharmadhikari
Dipti Thakkar
Jerome D. Boyd-Kirkup
Andrey Finegersh
Vasu Divi
John B. Sunwoo
John Aleman
Xiao-Jing Wang
Christina Kong
Lei Xing
Jennifer R. Cochran
Quynh-Thu Le
VISTA immune checkpoint blunts radiotherapy-induced antitumor immune response
Cell Reports
CP: Cancer
CP: Immunology
title VISTA immune checkpoint blunts radiotherapy-induced antitumor immune response
title_full VISTA immune checkpoint blunts radiotherapy-induced antitumor immune response
title_fullStr VISTA immune checkpoint blunts radiotherapy-induced antitumor immune response
title_full_unstemmed VISTA immune checkpoint blunts radiotherapy-induced antitumor immune response
title_short VISTA immune checkpoint blunts radiotherapy-induced antitumor immune response
title_sort vista immune checkpoint blunts radiotherapy induced antitumor immune response
topic CP: Cancer
CP: Immunology
url http://www.sciencedirect.com/science/article/pii/S2211124725006643
work_keys_str_mv AT dhanyaknambiar vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT sainiteeshmaddineni vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT jimpilangthasa vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT hongbincao vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT vigneshviswanathan vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT junyanliu vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT mdtauhidulislam vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT nishantmehta vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT jessicafrank vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT alexanderreal vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT tiacheunkarndee vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT eyiwunmieghonghonlaseinde vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT bhushandharmadhikari vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT diptithakkar vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT jeromedboydkirkup vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT andreyfinegersh vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT vasudivi vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT johnbsunwoo vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT johnaleman vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT xiaojingwang vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT christinakong vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT leixing vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT jenniferrcochran vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse
AT quynhthule vistaimmunecheckpointbluntsradiotherapyinducedantitumorimmuneresponse